Cypherpunk Technologies Inc.
CYPH • Healthcare
About Cypherpunk Technologies Inc.
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial.
Quality Assessment
Cypherpunk Technologies Inc. is a high-risk healthcare company with a Compass Score of 1. This stock has poor quality metrics and high risk. Not recommended for conservative investors.
Score Breakdown
The Compass Score is based on 6 quality factors identified by academic research.
Click any factor to see detailed metrics
Valuation Metrics
Click any metric for details
Technical Overview
Click any metric for details
Wall Street View
Growth Projections
Financial Health
Click any metric for details
Similar High-Quality Stocks
Important Disclaimer
The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.
Unlock Detailed Metrics
Upgrade to Basic to see the actual financial values behind each quality factor.
- See exact ROA, cash flow ratios, and more
- Unlimited stock lookups
- Export data to CSV
- 7-day free trial included
Cancel anytime